Azficel-T

DB11051ApprovedWithdrawnCell transplant therapiesAutologous Cultured Cell

Azficel-T is a medication composed of fibroblasts used to treat moderate to severe nasolabial wrinkles. Dermal fibroblasts are collected from the post-auricular biopsy tissue and aseptically expanded using standard tissue-culture procedures until sufficient cells for three doses are obtained.

Mechanism
Curator reviewed · 8 references
Primary indication
Indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.Curator reviewed · 1 structured indication
First approval
United States, 2011
Also known as
Autologous cultured fibroblasts

Resolves to

Clinical / RWD

What you can answer from here — as of March 06, 2025

188Drug interactionsStructured to mechanism, not free text
Sign in
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
7ContraindicationsEach with its own population and attribute set
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Azficel-T, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account